Tag: Professor Ben Solomon

Lilly launches LIBRETTO-431 clinical trial for selpercatinib in NSCLC

pharmanewsdaily- December 12, 2019

Eli Lilly and Company (Lilly) has initiated the phase 3 LIBRETTO-431 clinical trial to evaluate selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) ... Read More